Project Grant HT9425261E204
- Federal Project Grant Award Summary Award Details: Modulo Bio, Inc. received a $1.74M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of May 1, 2026, and a performance period through April 30, 2028. This administrative modification corrected the payment office DODAAC code for processing purposes without altering the award amount or other terms and conditions. Products and Services: Under this award,...
- Federal Grant Award Summary Wayfinder Biosciences Inc. received a $680,591 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel small molecule screening approach for direct and selective targeting of repeat expansion RNA in C9ORF72 Amyotrophic Lateral Sclerosis (ALS). The award, issued on June 15, 2025, with a completion date of December 14, 2026, funds hypothesis-driven biomedical research...
- Federal Project Grant Award Summary Sanford Burnham Prebys Medical Discovery Institute received a $1,078,882 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2025, through April 30, 2027. The award supports research applying chemical engineering approaches to amyotrophic lateral sclerosis (ALS) treatment, with a focus on advancing understanding of the multimodal therapeutic actions of donor and host neural...
- This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...
- The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $939,325 to the Weizmann Institute of Science on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support the GLOBALS (Global Omic Biomarker Research for ALS) initiative. This three-year project, extending through October 31, 2028, funds advanced biomedical research focused on discovering and developing omic biomarkers for amyotrophic lateral sclerosis (ALS). The research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $840,000 to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center under the Military Medical Research and Development program (CFDA 12.420) for the project "Targeting M6A Dysregulation in ALS via Small Molecule Approaches." The award, effective July 1, 2026, through June 30, 2028, supports research and development activities focused on investigating therapeutic interventions for...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Denver Research Institute a $2.31M Project Grant under the Military Medical Research and Development program (CFDA 12.420) beginning July 1, 2025, and concluding June 30, 2029. The award funds the Development and Evaluation of a Care Pathway for Evaluation and Management of the Respiratory Syndromes of Amyotrophic Lateral Sclerosis (CAPRESA), a clinical research initiative to be conducted at the Institute's Denver, Colorado...
- Federal Project Grant Award Summary Meso Scale Diagnostics LLC (doing business as Meso Scale Discovery) received a $997,807 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award supports the development of ultrasensitive immunoassays for detecting TDP-43 pathology, a biomarker associated with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). This...
- Federal Grant Award Summary Emory University received a $840,000 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period April 1, 2026 through March 31, 2028. The award supports research to repurpose approved drugs as first-in-class disruptors of the P38/MK2 (p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2) complex to suppress neuroinflammation in amyotrophic...
Award Details: Transposon Therapeutics, Inc. received a $1.92 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2026, with an ultimate completion date of February 14, 2028. The project, titled "Development of Human Line-1 Reverse Transcriptase Inhibitors for the Treatment of Amyotrophic Lateral Sclerosis," will be conducted in Laguna Niguel, California. Deliverables and Services: Under this award, Transposon Therapeutics will develop therapeutic compounds targeting Line-1 reverse transcriptase as a potential treatment approach for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The project encompasses research and development services focused on therapeutic development and translational research activities within the Military Medical Research and Development program's portfolio of biomedical research initiatives. This award reflects DHA's emphasis on supporting hypothesis-driven research addressing critical neurological conditions, aligning with the program's mission to deliver innovative medical solutions for both military service members and the American public.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.9m | 5/14/26 |